OSLO, Norway, Jan. 6, 2021 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors, today
announces that it has granted an extension of 3
months to the exclusive option agreement with IOVaxis Therapeutics
of Nantong, China, for clinical
development and licensing of the Targovax mutant RAS vaccines TG01
and TG02 in China, Hong Kong, Macau and Singapore.
On 8 January 2020 Targovax and
IOVaxis announced that they had entered into an exclusive option
agreement with 12-month validity for the development and
commercialization of Targovax's TG vaccines in Greater China and Singapore (see press release here). An
IND application to initiate clinical development of TG01 has been
submitted to the Chinese National Medical Products Administration
(NMPA), but the application preparation and regulatory review
process has been delayed due to COVID-19 related issues. To
accommodate the delay caused by these unforeseen circumstances,
Targovax has granted to IOVaxis an extension to the license option
period by 3 months. Otherwise, the option agreement remains
unchanged and in force.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA
Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-grants-iovaxis-3-months-extension-to-the-exclusive-license-option-for-tg-mutant-ras-vaccine,c3264497
View original
content:http://www.prnewswire.com/news-releases/targovax-grants-iovaxis-3-months-extension-to-the-exclusive-license-option-for-tg-mutant-ras-vaccines-in-greater-china-and-singapore-301201725.html
SOURCE Targovax